byiShook Opinion
Mar 18, 2025 - 11:05
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure. The post Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies appeared first on Investor's Business Daily.
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
The post Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies appeared first on Investor's Business Daily.